Latest Healthcare News

Arena REIT faces a rent payment default from key tenant Edge Early Learning, representing 14% of rental income, prompting default notices and a delay in FY2026 financial results.

Talius has secured a substantial $850,000 purchase order from New Zealand’s Hato Hone St John, adding 8,000 devices and boosting its recurring revenue by $55,000 annually.

Flagship Investments Limited reported a sharp 24.1% portfolio decline for the year ended 30 June 2026, underperforming the ASX All Ordinaries Index by 21.7 percentage points. Despite this, the company declared a fully franked final dividend of 5.3 cents per share, supported by retained earnings.

Kingfish Limited posted a net loss of NZD 13.6 million for FY2026, underperforming the NZX50 benchmark, but showed early signs of recovery in FY2027. The company re-elected two directors and maintained its focus on quality growth stocks amid a cautious economic outlook.

Resmed delivered a strong FY2026 with 10% revenue growth to $5.7 billion, a 17% rise in non-GAAP EPS, and a 10% dividend hike. Strategic moves include selling MatrixCare and acquiring Noctrix Health.

AVITA Medical posted robust Q2 2026 results with 18% revenue growth, driven by RECELL and supported by Cohealyx and PermeaDerm, and now expects to reach cash flow breakeven by year-end.

Wellnex Life has agreed to sell its Pain Away brand to Mentholatum Australasia for up to A$21.3 million, aiming to wipe out debt and sharpen its strategic focus.

Clarity Pharmaceuticals has presented compelling clinical evidence that its investigational 64Cu-SAR-bisPSMA diagnostic and 67Cu-SAR-bisPSMA therapeutic candidates outperform current standards in prostate cancer care, positioning the company for regulatory and commercial milestones.

Argent BioPharma's licensing partner Splash Beverage Group has launched the US veterinary development program for CannEpil®, targeting companion-animal oncology and chronic pain. Led by industry veteran Dr Hunter Land, the initiative follows a defined FDA regulatory pathway and could broaden CannEpil®’s commercial footprint beyond human neurology.

Acrux Limited spotlighted its Female Testosterone Metered Dose Transdermal System (MDTS) at the Bioshares Biotech Summit, revealing positive Phase II data and outlining a clear regulatory and commercial roadmap targeting Hypoactive Sexual Desire Disorder (HSDD) in women.

Integral Diagnostics has installed Jason Martinez as its new CEO, marking a leadership change as the company prepares to present its FY26 results. Martinez brings over 20 years of diagnostic imaging experience and aims to drive growth and innovation following the retirement of long-serving CEO Ian Kadish.

Osteopore has inked a three-year distribution agreement with Al-Umnia Medical to bring its 3D-printed orthopaedic implants to five Gulf countries, targeting a rapidly expanding regional market.